arrow
A

Andrea Lo

british columbia cancer
H指数:20
被引数:1,347

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses

IA期NLPHL患者的临床结局:全球NLPHL工作组(GLOW)回顾性分析

2026-04-160
OAAI
Subsequent Neoplasm Risk after Modern Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Insights from a Multi-Institutional Children’s Oncology Group Trial
2026-02-060
PRE
Enhancing Radiation Therapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131
2025-12-240
PRE
Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups

淋巴瘤试验的辐射目标命名: 国家临床试验网络小组的共识建议

2024-12-010
PRE
Impact of Myc-Altered Pathology on Radiation Therapy Efficacy Among Patients With Relapsed/Refractory Large-B Cell Lymphoma A Collaborative Study by ILROG

Myc-改变的病理对复发/难治性大B细胞淋巴瘤患者放疗疗效的影响 ILROG合作研究

2024-11-010
PRE
Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)

复发和难治性全身治疗的真实世界结局:加拿大小细胞肺癌数据库(CASCADE)

2024-09-010
PRE
Long-term outcomes and patterns of relapse in patients with bilateral Wilms tumor or bilaterally predisposed unilateral Wilms tumor, a report from the COG AREN0534 study
2024-07-083
PRE
PROTON BEAM THERAPY (PBT) FOR CENTRAL NERVOUS SYSTEM (CNS) TUMOURS IN CHILDREN: A CANADIAN PEDIATRIC BRAIN TUMOUR CONSORTIUM STUDY
2024-06-180
OAAI
Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children's Oncology Group Study, AREN03B2
2024-03-151
PRE
Low-grade diffusely infiltrative tumour (LGDIT), SMARCB1-mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC

SMARCB1-mutant低度弥漫性浸润性肿瘤 (LGDIT): 与atrt-myc具有表观遗传相似性的临床和组织病理学独特实体

2022-02-187
OAAI
Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach

局限性结节性淋巴细胞为主的霍奇金淋巴瘤的结局以及PET适应方法的影响

2021-09-246
OA